Share

Slough, UK, 20 November 2018 – Indivior PLC (LON: INDV) “Indivior is disappointed that the U.S. Court of Appeals for the Federal Circuit has vacated the preliminary injunction against Dr. Reddy’s Laboratories (“DRL”). Indivior will continue to vigorously pursue ongoing infringement cases against DRL to protect its SUBOXONE® (buprenorphine and naloxone) Sublingual Film patent portfolio. The Company is in the process of interpreting the ruling in its entirety and will issue a statement on its implications once this review has been completed.”

For Further Information

Investor Enquiries
Jason Thompson
VP Investor Relations, Indivior PLC
+1 804 379 1033
jason.thompson@indivior.com

Media Enquiries
Jonathan Sibun
Tulchan Communications US Media Enquiries
+44 207 353 4200 +1 804 594 0836
Indiviormediacontacts@indivior.com

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Privacy Policy Cookie Notice

Manage Consent Preferences

Always Active